Wildcat Capital Management LLC Purchases New Shares in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA)

Wildcat Capital Management LLC acquired a new stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 281,859 shares of the company's stock, valued at approximately $4,053,000. Centessa Pharmaceuticals comprises about 2.2% of Wildcat Capital Management LLC's investment portfolio, making the stock its 6th biggest position. Wildcat Capital Management LLC owned about 0.21% of Centessa Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Geode Capital Management LLC raised its position in Centessa Pharmaceuticals by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 57,257 shares of the company's stock worth $959,000 after buying an additional 660 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Centessa Pharmaceuticals in the 4th quarter valued at $31,000. Barclays PLC grew its stake in Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after acquiring an additional 4,952 shares during the period. Franklin Resources Inc. grew its stake in Centessa Pharmaceuticals by 0.3% in the 4th quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company's stock valued at $38,668,000 after acquiring an additional 6,000 shares during the period. Finally, Squarepoint Ops LLC grew its stake in Centessa Pharmaceuticals by 33.2% in the 4th quarter. Squarepoint Ops LLC now owns 26,806 shares of the company's stock valued at $449,000 after acquiring an additional 6,685 shares during the period. 82.01% of the stock is owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Price Performance

Shares of CNTA stock traded down $0.27 during mid-day trading on Friday, reaching $15.69. The stock had a trading volume of 1,007,312 shares, compared to its average volume of 775,889. The company has a market cap of $2.10 billion, a P/E ratio of -8.67 and a beta of 1.45. The business has a 50-day simple moving average of $13.24 and a 200 day simple moving average of $14.42. Centessa Pharmaceuticals PLC Sponsored ADR has a 12-month low of $9.00 and a 12-month high of $19.09. The company has a current ratio of 14.37, a quick ratio of 14.37 and a debt-to-equity ratio of 0.28.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.15. On average, sell-side analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Arjun Goyal purchased 417,646 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, May 16th. The shares were purchased at an average cost of $12.73 per share, with a total value of $5,316,633.58. Following the transaction, the director owned 462,585 shares of the company's stock, valued at approximately $5,888,707.05. The trade was a 929.36% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Gregory M. Weinhoff sold 11,742 shares of the business's stock in a transaction that occurred on Friday, April 25th. The stock was sold at an average price of $13.61, for a total value of $159,808.62. Following the transaction, the insider directly owned 122,279 shares in the company, valued at $1,664,217.19. This trade represents a 8.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 189,398 shares of company stock worth $2,462,692. 7.09% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have issued reports on CNTA. Oppenheimer began coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, May 8th. They set an "outperform" rating and a $6.00 target price on the stock. Piper Sandler assumed coverage on shares of Centessa Pharmaceuticals in a research report on Monday, March 31st. They set an "overweight" rating and a $38.00 price target on the stock. Wall Street Zen upgraded shares of Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Needham & Company LLC began coverage on shares of Centessa Pharmaceuticals in a research note on Wednesday, May 28th. They set a "buy" rating and a $35.00 price target on the stock. Finally, Chardan Capital started coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, May 8th. They set a "buy" rating and a $30.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, Centessa Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $27.89.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.